

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandra, Virginia 22313-1450
www.uspo.gov

PPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/645,556	08/25/2000	Bernward Scholkens	02481.1702	3278	
22852 - 7590 01/24/2005			EXAMINER		
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER			kim, jennifer m		
LLP 901 NEW YOR	K AVENUE, NW		ART UNIT	PAPER NUMBER	
WASHINGTON, DC 20001-4413			1617		

DATE MAILED: 01/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

(*)	.)	Application No.	Applicant(s)					
Advisory Action	`	09/645,556	SCHOLKENS ET A	L.				
Advisory Action (Supplemental)		Examiner	Art Unit					
(3 10	ʻ	Jennifer Kim	1617					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
THE REPLY FILED 06 December 2004 FA Therefore, further action by the applicant is final rejection under 37 CFR 1.113 may onl condition for allowance; (2) a timely filed No Examination (RCE) in compliance with 37 C	required to a y be either: (1 ptice of Appe	void abandonment of this ap	oplication. A proper re	ply to a				
		PLY [check either a) or b)]						
a) The period for reply expires 5 months from t b) The period for reply expires on: (1) the mailin event, however, will the statutory period for re ONLY CHECK THIS BOX WHEN THE FIR: 706.07(f).	g date of this Adv ply expire later the ST REPLY WAS	isory Action, or (2) the date set forth an SIX MONTHS from the mailing da FILED WITHIN TWO MONTHS OF	ate of the final rejection. THE FINAL REJECTION.	See MPEP				
Extensions of time may be obtained under 37 CFR have been filed is the date for purposes of determining the 37 CFR 1.17(a) is calculated from; (1) the expiration date (b) above, if checked. Any reply received by the Office is earned patent term adjustment. See 37 CFR 1.704(b).	e period of extens of the shortened	sion and the corresponding amount o	of the fee. The appropriate ex	dension fee under				
1. A Notice of Appeal was filed on 37 CFR 1.192(a), or any extension the	Appellant's nereof (37 CF	s Brief must be filed within th R 1.191(d)), to avoid dismiss	ne period set forth in sal of the appeal.					
2. ✓ The proposed amendment(s) will not	be entered be	ecause:						
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);								
(b) they raise the issue of new matter (see Note below);								
(c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or								
(d) they present additional claims without canceling a corresponding number of finally rejected claims.								
NOTE: <u>See Continuation Sheet.</u>								
3. Applicant's reply has overcome the f								
 Newly proposed or amended claim(s) canceling the non-allowable claim(s)) would	be allowable if submitted in	a separate, timely file	d amendment				
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) application in condition for allowance	request fo because:	r reconsideration has been o	onsidered but does No	OT place the				
6. The affidavit or exhibit will NOT be craised by the Examiner in the final re	onsidered bed	cause it is not directed SOLE	LY to issues which we	ere newly				
7. For purposes of Appeal, the proposed explanation of how the new or amen	d amendment ded claims w	(s) a) will not be entered o	or b) will be entered below or appended.	and an				
The status of the claim(s) is (or will b			,,					
Claim(s) allowed:								
Claim(s) objected to:								
Claim(s) rejected: 4,6,7,18 and 19.								
Claim(s) withdrawn from consideration	on:							
8. The drawing correction filed on		roved or b) disapproved	by the Examiner					
9. Note the attached Information Disclos			73//					
10. Other:		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	The Vision	allan				
			EENI PADMAKABHAN ISORY PATENT EXAM					

Continuation Sheet (PTOL-303)

Application No.

Continuation of 2. NOTE: Newly submitted claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention since the term "human" lacks literal support in the specification as filed. Applicants argue the specification provides written description support for the amended claims, including support for the treatment of a "human" who exhibits normal or low blood pressure and for instance, the specification in the fourth full paragraph on page 3 mentions that a suitable definition of normal or low blood pressure can be found in JNC VI, which was incorporated by reference. This is not persuasive because the attempt to incorporate subject matter into this application by reference to claiming "human" is improper because the incorporation of essential material in the specification by reference to a foreign application or patent, or to a publication is improper. Applicant is required to amend the disclosure to include the material incorporated by reference. The amendment must be accompanied by an affidavit or declaration executed by the applicant, or a practitioner representing the applicant, stating that the amendatory material consists of the same material incorporated by reference in the referencing application. See In re Hawkins, 486 F.2d 569, 179 USPQ 157 (CCPA 1973); In re Hawkins, 486 F.2d 579, 179 USPQ 163 (CCPA 1973); and In re Hawkins, 486 F.2d 577, 179 USPQ 167 (CCPA 1973). IDS (Information Disclosure Statement-PTO-1449) filed 11/8/2004 has not been considered since there is no petition to consider IDS after final.